With zero observations
Shilpa Medicare announced that the USFDA has concluded Remote Record Review of Shilpa Medicare ('SML' or 'the Company), Unit III, Research and Development facility situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15 to 18 November 2021.Shilpa Medicare's Unit III, R&D facility is involved in development of formulations (generics, complex generics and innovative products) and providing advanced analytical services.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content